1,298 material Form 8-K filings that 1,057 companies we cover made with the SEC in April 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
AptarGroup reported first-quarter 2026 sales up 11% to $982.9 million, but core sales were flat and reported net income fell 8% to $73 million. Adjusted EPS was $1.19, down from $1.30 a year earlier at comparable exchange rates, and the company guided second-quarter adjusted EPS to $1.32 to $1.40. The filing also names Gael Touya as the next CEO, effective September 1, 2026.
Reported sales rose 11% to $982.9 million; core sales were flat versus the prior year quarter.
Reported EPS fell 4% to $1.12; adjusted EPS fell 8% to $1.19 from $1.30 at comparable exchange rates.
Q2 2026 adjusted EPS guidance is $1.32 to $1.40, versus $1.67 in Q2 2025 per the filing's reconciliation table.
Gael Touya named Aptar's next CEO effective September 1, 2026.
Camden Property Trust reported first quarter 2026 net income attributable to common shareholders of $42.4 million, or $0.40 per diluted share, up from $0.36 a year earlier, but FFO fell to $1.15 per share from $1.70 and Core FFO slipped to $1.70 from $1.72. The company cut its 2026 FFO guidance midpoint to $6.10 from $6.61, raised its EPS midpoint to $0.66 from $0.55, and left its Core FFO midpoint unchanged at $6.75.
Q1 2026 EPS $0.40 vs. $0.36 a year earlier; FFO $1.15 vs. $1.70; Core FFO $1.70 vs. $1.72
Property revenues $388.8 million vs. $390.6 million; same property NOI down 0.7% year over year
Subsequent to quarter end, agreed to pay $53.0 million into a settlement fund for class action litigation over revenue management software
2026 FFO guidance range $5.95 to $6.25 per share; Core FFO guidance range $6.60 to $6.90 per share
MasTec reported first-quarter 2026 revenue of $3.8 billion, up 34% from a year earlier, and GAAP diluted EPS of $0.77 versus $0.13. The company raised its full-year 2026 diluted EPS guidance to $6.77 and its adjusted diluted EPS guidance to $8.79, and it gave second-quarter 2026 revenue guidance of $4.3 billion.
Q1 2026 revenue $3.8 billion, up 34% year over year; adjusted diluted EPS $1.39 versus $0.51
Record 18-month backlog of $20.3 billion as of March 31, 2026, up $4.4 billion year over year
Full-year 2026 guidance: diluted EPS $6.77 and adjusted diluted EPS $8.79, both raised
Apple reported fiscal second-quarter 2026 revenue of $111.2 billion, up 17% from a year earlier, and diluted EPS of $2.01, up 22%. The board raised the quarterly dividend 4% to $0.27 per share and authorized an additional $100 billion share repurchase program, which returns more capital to shareholders.
Quarter ended March 28, 2026: total net sales $111.2 billion, up from $95.4 billion a year earlier
Diluted EPS $2.01, compared with $1.65 a year earlier; operating cash flow over $28 billion
Quarterly dividend raised 4% to $0.27 per share, payable May 14, 2026, to holders of record as of May 11, 2026
Board authorized an additional repurchase program of up to $100 billion of common stock
Encompass Health reported first-quarter 2026 net operating revenue of $1,586.6 million, up 9.0%, and diluted earnings per share from continuing operations of $1.77, up from $1.48 a year earlier. The company raised its full-year 2026 guidance for revenue, Adjusted EBITDA, and adjusted earnings per share, though adjusted free cash flow declined 12.9%.
Q1 2026 net operating revenue was $1,586.6 million versus $1,455.4 million, up 9.0%
Q1 2026 diluted EPS from continuing operations was $1.77 versus $1.48; adjusted EPS was $1.60 versus $1.37
Full-year 2026 guidance: net operating revenue raised to $6,375 million to $6,470 million; adjusted EPS raised to $5.89 to $6.11
Adjusted free cash flow was $193.8 million, down from $222.4 million, and included a $17.5 million pre-tax gain on the sale of Gamma Knife
Park Hotels & Resorts reported first quarter 2026 results, with net income of $12 million compared with a $57 million loss a year earlier, while total revenue fell to $622 million from $630 million. The company raised its full-year Adjusted EBITDA and RevPAR outlook but lowered its net income and diluted EPS outlook, so the results send mixed signals to shareholders.
Q1 2026 total revenue $622 million vs $630 million in Q1 2025; Adjusted EBITDA $143 million vs $144 million
Q1 diluted EPS $0.05 vs a loss of $0.29 a year earlier; Q1 2025 included a $70 million impairment
Full-year 2026 Adjusted EBITDA outlook raised to $587 million-$617 million from $580 million-$610 million
Full-year 2026 diluted EPS outlook lowered to $0.29-$0.44 from $0.31-$0.46; $0.25 Q2 dividend payable July 15, 2026
The Ensign Group reported first-quarter 2026 results with GAAP diluted EPS of $1.67, up from $1.37 a year earlier, and revenue of $1.39 billion, up 18.4%. The company raised its 2026 earnings guidance to $7.48 to $7.62 per diluted share and its revenue guidance to $5.81 billion to $5.86 billion, citing the quarter's strength and recent acquisitions, which points to higher expected profit and sales for shareholders.
GAAP diluted EPS was $1.67 versus $1.37 in Q1 2025; adjusted diluted EPS was $1.85, up 21.7%
GAAP net income was $99.7 million, up 24.2%; consolidated revenue was $1.39 billion, up 18.4%
2026 diluted EPS guidance raised to $7.48 to $7.62 from $7.41 to $7.61; revenue guidance raised to $5.81 billion to $5.86 billion from $5.77 billion to $5.84 billion
Cash on hand was $539.5 million at March 31, 2026, with $591.6 million of available line-of-credit capacity
Floor & Decor reported first-quarter fiscal 2026 net sales of $1.15 billion, down 0.7%, with diluted EPS of $0.37 versus $0.45 a year earlier, and comparable store sales fell 3.7%. The company also issued fiscal 2026 guidance of diluted EPS of approximately $1.83 to $2.08 and announced a share repurchase program of up to $400 million, approved by its board on April 23, 2026.
Net sales of $1,152.3 million, down 0.7% from $1,160.7 million; comparable store sales down 3.7%
Diluted EPS of $0.37, down 17.8% from $0.45; net income of $39.7 million, down 18.8%
Fiscal 2026 outlook: diluted EPS of approximately $1.83 to $2.08 and comparable store sales of approximately (4.0)% to flat
$400 million share repurchase program approved April 23, 2026, with no expiration date and no obligation to repurchase
Allegiant reported first-quarter 2026 total operating revenue of $732.4 million, up 4.8% from a year earlier, and GAAP diluted earnings of $2.30 per share versus $1.73. The company guided second-quarter adjusted EPS to a loss of $1.00 to $0.00, excluding the planned Sun Country acquisition, and disclosed two credit facilities that together allow borrowing of up to $291 million. Shareholders see higher first-quarter profit alongside a weaker second-quarter outlook and more debt.
Q1 2026 revenue $732.4 million, up 4.8% year over year; GAAP diluted EPS $2.30 vs. $1.73; adjusted airline-only diluted EPS $3.77, up 78.7%
Q2 2026 guidance: adjusted EPS of ($1.00) to $0.00 and adjusted operating margin of 0.0% to 2.0%, stand-alone basis
Credit facilities signed April 27 ($115 million, fully drawn) and April 28 ($176 million, first advance of $44.0 million expected in early May 2026)
Sun Country acquisition could close as early as mid-May, per CEO Gregory Anderson
Corcept reported first quarter 2026 revenue of $164.9 million, up from $157.2 million a year earlier, but swung to a net loss of $31.8 million from net income of $20.5 million, as operating expenses rose to $214.5 million from $153.8 million. The company raised its 2026 revenue guidance to $950 million to $1,050 million and said it expects to return to profitability in the second quarter of 2026.
Revenue was $164.9 million versus $157.2 million in Q1 2025; diluted net loss per share was $0.30 versus diluted earnings of $0.17.
Operating expenses were $214.5 million versus $153.8 million, driven by spending to prepare for the Lifyorli launch and growth initiatives in the Cushing's syndrome business.
2026 revenue guidance was increased to $950 million to $1,050 million.
Cash and investments were $515.4 million at March 31, 2026, down from $532.4 million at December 31, 2025.
LPL Financial reported first quarter 2026 net income of $356 million, or $4.43 per diluted share, up from $4.24 a year earlier, and adjusted EPS of $5.60. The company also lowered the upper end of its 2026 Core G&A outlook by $20 million and reduced its estimated Commonwealth run-rate EBITDA, which shareholders may weigh against the stronger quarter.
Net income was $356 million, with diluted EPS of $4.43 versus $4.24 in Q1 2025; adjusted EPS was $5.60, up 9% year over year
Total revenue was $4.94 billion, flat from the prior quarter and up 35% from a year ago
2026 Core G&A outlook upper end lowered by $20 million to a range of $2,155-2,190 million
Estimated Commonwealth run-rate EBITDA decreased from $425 million to $410 million; conversion on track for Q4 2026
Five9 reported first quarter 2026 revenue of $305.3 million, up 9% from $279.7 million a year earlier, with GAAP net income of $18.4 million ($0.21 per diluted share) versus $0.6 million ($0.01) in the prior-year quarter. The company also announced a $90 million accelerated share repurchase to finish its $150 million program and authorized a new $200 million buyback, and it gave second-quarter and full-year 2026 guidance.
Q1 2026 revenue $305.3 million, up 9%; Q1 subscription revenue grew 13% year over year.
GAAP net income $18.4 million, or $0.21 per diluted share, versus $0.01 in Q1 2025; non-GAAP net income $58.6 million, or $0.76 per diluted share.
Q2 2026 revenue guidance $303.0 to $309.0 million; Q2 GAAP net loss per share guided at $(0.09) to $0.00.
Board authorized a new share repurchase program of up to $200 million of common stock.
Illumina reported first-quarter 2026 revenue of $1.09 billion, up 4.8% from a year earlier, and non-GAAP diluted EPS of $1.15 versus $0.97. The company raised its fiscal 2026 non-GAAP EPS guidance and its board authorized a new $1.5 billion share repurchase program, which adds to remaining capacity under the 2024 program.
Q1 2026 revenue $1.09 billion, up 4.8% from Q1 2025; GAAP diluted EPS $0.87 versus $0.82
Non-GAAP diluted EPS $1.15 versus $0.97 in Q1 2025; GAAP net income $134 million versus $131 million
FY2026 non-GAAP diluted EPS guidance raised to $5.15-$5.30 from $5.05-$5.20; revenue guidance raised $20 million at the midpoint to $4.52-$4.62 billion
Board authorized up to $1.5 billion in new buybacks on April 28, 2026; about $314 million remained under the August 2024 program as of April 29, 2026
Sandisk reported fiscal third-quarter revenue of $5.95 billion, up 97% from the prior quarter and above its guidance range, with GAAP diluted net income per share of $23.03 versus $5.15 in the second quarter. The company guided fiscal fourth-quarter revenue to $7.75 billion to $8.25 billion and non-GAAP diluted EPS to $30.00 to $33.00, and its board approved a $6 billion share repurchase program that the company expects to fund from operating cash flows.
Q3 revenue of $5.95 billion, up 97% sequentially; Datacenter revenue of $1.47 billion, up 233%
GAAP diluted EPS of $23.03 (non-GAAP $23.41) for the quarter ended April 3, 2026, versus $5.15 in the prior quarter
Q4 fiscal 2026 guidance: revenue of $7.75 billion to $8.25 billion; non-GAAP diluted EPS of $30.00 to $33.00
Board approved a $6 billion share repurchase program; the company may suspend or discontinue it at any time
Western Digital reported fiscal third-quarter 2026 revenue of $3.34 billion, up 45% from a year earlier, with GAAP diluted EPS of $8.20 versus $2.11. GAAP results include a $2.7 billion gain on its retained Sandisk interest, while non-GAAP diluted EPS was $2.72, up 97%. The company also guided fiscal fourth-quarter revenue to $3.65 billion, plus or minus $100 million, and raised its quarterly dividend 20% to $0.15 per share.
Q3 FY26 revenue $3.34 billion, up 45% year over year; GAAP gross margin 50.2%, non-GAAP 50.5%
GAAP diluted EPS $8.20 vs $2.11 a year earlier; non-GAAP diluted EPS $2.72 vs $1.38
Cohu reported first quarter 2026 net sales of $125.1 million, up from $96.8 million a year earlier, and a GAAP net loss of $12.1 million, or $0.26 per share, compared with a $30.8 million loss a year earlier. The company raised its FY26 high-performance computing revenue outlook to approximately $80-100 million and guided second quarter 2026 sales to $144 million, plus or minus $7 million.
Q1 2026 net sales $125.1 million vs. $96.8 million in Q1 2025; Q4 2025 was $122.2 million
GAAP net loss $12.1 million ($0.26 per share) vs. $30.8 million ($0.66 per share) in Q1 2025; non-GAAP net income $0.6 million ($0.01 per share)
FY26 high-performance computing revenue outlook raised to approximately $80-100 million
Q2 2026 sales expected at $144 million +/- $7 million; cash and investments $488.7 million at quarter end
Columbia Sportswear reported first quarter 2026 net sales of $779.0 million, roughly flat year over year and down 3 percent on a constant-currency basis, while operating income fell 10 percent to $42.0 million and diluted earnings per share were $0.65 versus $0.75. The company raised its full-year 2026 diluted EPS guidance to $3.55 to $4.00 from $3.20 to $3.65, citing in part a temporary improvement in U.S. tariff rates, but it expects a loss per share in the second quarter.
Q1 2026 net sales were $779.0 million versus $778.5 million a year earlier; U.S. net sales fell 10 percent to $422.5 million
Full-year 2026 net sales guidance was unchanged at $3.43 to $3.50 billion, while diluted EPS guidance was raised to $3.55 to $4.00 from $3.20 to $3.65
Second-quarter 2026 diluted loss per share is expected to be $0.37 to $0.46, compared with a $0.19 loss in the second quarter of 2025
Board declared a $0.30 quarterly dividend payable June 4, 2026 to shareholders of record May 21, 2026; the company repurchased $150.0 million of stock in Q1
Zeta Global reported first-quarter 2026 revenue of $396 million, up 50% from a year earlier, and raised its full-year 2026 revenue guidance by $30 million at the midpoint. The net loss narrowed to $13.2 million from $21.6 million, although adjusted EBITDA margin slipped to 16.7% from 17.7%. For shareholders, the results and higher outlook show faster revenue growth, though the company still reported a net loss for the quarter.
Q1 2026 revenue of $396 million, up 50% year over year, exceeded the guidance midpoint by $26 million.
Net loss narrowed to $13.2 million from $21.6 million in Q1 2025.
Adjusted EBITDA rose to $66.1 million from $46.7 million; adjusted EBITDA margin was 16.7% versus 17.7%.
Full-year 2026 revenue guidance raised to $1,779 million to $1,792 million, up $30 million at the midpoint from $1,755 million; Q2 revenue guidance is $419 million to $422 million.
Dexcom reported first-quarter 2026 revenue of $1.192 billion, up 15% from a year earlier, and GAAP net income of $199.5 million, or $0.51 per diluted share, versus $105.4 million, or $0.27, in the first quarter of 2025. The company raised its fiscal 2026 guidance for Non-GAAP Operating Margin and Adjusted EBITDA Margin and reiterated its revenue guidance of $5.16 billion to $5.25 billion.
Revenue grew 15% year-over-year to $1.192 billion; organic revenue grew 12% to $1.165 billion.
GAAP operating income was $255.3 million, or 21.4% of revenue, up from $133.7 million, or 12.9%, a year earlier.
Fiscal 2026 guidance raised for Non-GAAP Operating Margin (approximately 23% to 23.5%) and Adjusted EBITDA Margin (approximately 31% to 31.5%); revenue guidance reiterated at $5.16 billion to $5.25 billion.
Cash, cash equivalents and marketable securities totaled $2.42 billion as of March 31, 2026.
Roku reported first-quarter 2026 results on April 30, 2026, with total net revenue of $1.25 billion, up 22% year over year, and net income of $86 million, compared with a net loss of $27 million a year earlier. The company said it is raising its full-year 2026 outlook, now expecting total net revenue of $5.5 billion and Adjusted EBITDA of $675 million.
Q1 2026 total net revenue was $1.25 billion, up 22% YoY; Platform revenue was $1.13 billion, up 28%
Net income was $86 million in Q1 2026, versus a net loss of $27 million in Q1 2025; Adjusted EBITDA was $148 million, up 165% YoY
Q2 2026 outlook: total net revenue of $1.3 billion and Adjusted EBITDA of $170 million; full-year 2026 total net revenue of $5.5 billion and Adjusted EBITDA of $675 million
Devices revenue fell 16% YoY to $118 million; the company disclosed $100 million of Q1 share repurchases
Alignment Healthcare reported first-quarter 2026 total revenue of $1,235.2 million, up 33.3% year-over-year, and net income of $11.4 million, compared with a net loss of $9.4 million a year earlier. The company also raised the midpoint of its membership, revenue, adjusted gross profit and adjusted EBITDA guidance for 2026, which shows a higher outlook alongside the profit improvement.
Total revenue was $1,235.2 million for the quarter ended March 31, 2026, up 33.3% from the prior-year quarter.
Net income was $11.4 million, versus a $9.4 million net loss in Q1 2025; diluted EPS was $0.05.
Adjusted EBITDA was $37.9 million, up 87.6% year-over-year; health plan membership was about 284,800, up 30.9%.
Full-year 2026 revenue guidance is $5.16 billion to $5.205 billion, and adjusted EBITDA guidance is $138 million to $163 million.
TriMas reported first quarter 2026 net sales of $168.3 million, up 10.4%, and a loss from continuing operations of $51.8 million, or $1.38 per diluted share, versus income of $1.9 million a year earlier. The loss was driven mainly by a $53.9 million non-cash tax impact tied to the March 16, 2026 sale of TriMas Aerospace, while adjusted diluted EPS from continuing operations rose to $0.24 from $0.15. The company reaffirmed its 2026 sales and margin outlook and issued full-year adjusted diluted EPS guidance of $1.50 to $1.70.
Net sales were $168.3 million, up 10.4% from $152.5 million, with organic growth of 7.3%.
GAAP loss from continuing operations was $51.8 million, or $1.38 per diluted share, including a $53.9 million non-cash tax impact from the TriMas Aerospace divestiture.
Adjusted diluted EPS from continuing operations was $0.24, compared with $0.15 in the prior year period.
Full-year 2026 adjusted diluted EPS guidance is $1.50 to $1.70; sales growth of 3% to 6% was reaffirmed.
Dream Finders Homes reported first quarter 2026 results for the three months ended March 31, 2026. Net income attributable to the company fell to $13 million, or $0.11 per basic share, from $55 million, or $0.55 per basic share, a year earlier, while net sales rose 19% to a record 2,408 and homebuilding revenues fell 14% to $837 million. The company reiterated its full-year 2026 guidance of approximately 9,250 home closings.
Net income attributable to DFH was $13 million, or $0.11 per basic share, versus $55 million, or $0.55, in Q1 2025.
Homebuilding revenues were $837 million, down 14%, and homebuilding gross margin was 14.5% versus 19.2%.
Net sales were 2,408, up 19%, and the cancellation rate improved to 7.5% from 11.7%.
The company reiterated its 2026 guidance of approximately 9,250 home closings.
Illinois Tool Works reported first-quarter 2026 revenue of $4.02 billion, up 4.6%, and GAAP earnings per share of $2.66, up 12%. The company raised its full-year 2026 GAAP EPS guidance by $0.10 to a range of $11.10 to $11.50, so shareholders get higher profit expectations, though organic revenue growth was only 0.4% and foreign currency added 3.9 points.
Q1 revenue $4.02 billion, up 4.6%; organic growth 0.4%, with foreign currency adding 3.9 points
Q1 GAAP EPS $2.66 versus $2.38 diluted a year earlier; operating margin 25.4%, up 60 basis points
Full-year 2026 GAAP EPS guidance raised by $0.10 to $11.10-$11.50; revenue growth of 2%-4% projected
Q1 share repurchases of $375 million; about $1.5 billion of buybacks expected in 2026
NNN REIT reported first quarter 2026 results on April 30, 2026, with revenue of $240.4 million, up from $230.9 million a year earlier, while net earnings fell to $94.0 million from $96.5 million. The company raised its 2026 AFFO and Core FFO per share guidance by one cent at each end of the range.
Revenue of $240.4 million vs. $230.9 million in Q1 2025; net earnings of $94.0 million vs. $96.5 million.
Diluted EPS of $0.50 vs. $0.51; AFFO per diluted share of $0.87, unchanged year over year.
2026 AFFO per share guidance raised to $3.53 to $3.59 from $3.52 to $3.58; Core FFO per share guidance raised to $3.48 to $3.54 from $3.47 to $3.53.
Portfolio occupancy was 98.6% at March 31, 2026, up from 97.7% a year earlier.
Alnylam reported first-quarter 2026 total revenues of $1.17 billion, up 96% from $594 million a year earlier, with AMVUTTRA driving most of the growth. GAAP net income was $206 million, or $1.51 per diluted share, compared with a net loss of $18 million a year earlier. The company reiterated, rather than changed, its full-year 2026 guidance for total net product revenues of $4.9 billion to $5.3 billion.
Total revenues of $1.17 billion in Q1 2026, up 96% from $594 million in Q1 2025.
GAAP net income of $206 million, or $1.51 per diluted share, versus a net loss of $18 million, or $0.14 per share, a year earlier.
Total net product revenues of $1.04 billion, up 121%; AMVUTTRA contributed $890 million.
Full-year 2026 total net product revenues guidance of $4.9 billion to $5.3 billion was reiterated.
Hubbell reported first-quarter 2026 net sales of $1.5 billion, up 11% from a year earlier, and GAAP diluted EPS of $3.41, up 13% from $3.03. The company raised its full-year 2026 diluted EPS range to $17.45 to $18.00 and its adjusted diluted EPS range to $19.30 to $19.85, which matters to shareholders because it lifts the company's expected earnings for the year.
Q1 2026 net sales were $1,516.7 million, up from $1,365.2 million; organic sales grew 8.2%.
Q1 2026 GAAP diluted EPS was $3.41 versus $3.03; adjusted diluted EPS was $3.93 versus $3.38, up 16%.
Q1 2026 operating income was $263.8 million versus $230.4 million, and the operating margin was 17.4%.
Full-year 2026 GAAP diluted EPS guidance was raised to $17.45 to $18.00; adjusted diluted EPS guidance is $19.30 to $19.85.
Integer Holdings Corporation reported first quarter 2026 sales up 0.5% to $440 million, while adjusted EPS fell 8% to $1.20. The Board also began a strategic review to maximize stockholder value, which may include a sale, merger, or business combination, with no set timeline and no assurance of a transaction. The company updated its 2026 outlook, with adjusted EPS now expected at $5.83 to $6.40, a change of (9)% to 0% from the prior year.
Q1 2026 sales rose 0.5% to $440 million, with organic growth of 1.3%; GAAP income from continuing operations was $17 million, versus a loss of $22 million a year earlier.
Q1 2026 adjusted EPS fell $0.11 to $1.20, and adjusted operating income fell 14% to $61 million.
2026 outlook: adjusted EPS of $5.83 to $6.40 and adjusted operating income of $285 million to $305 million; management said it was prudent to further risk adjust the outlook.
Total debt rose $66 million to $1.252 billion since the end of 2025; leverage ratio was 3.2 times adjusted EBITDA as of April 3, 2026.
Belden reported first quarter 2026 revenue of $696 million, up 11% from a year earlier, and adjusted EPS of $1.77, up 11%. On the same day it announced a definitive agreement to acquire RUCKUS Networks from Vistance Networks for approximately $1.85 billion, and it guided second quarter 2026 revenue to $735 million to $750 million on a standalone basis.
Q1 2026 revenue $696 million, up 11% (7% organic); GAAP EPS $1.30 vs. $1.27 a year earlier
Q1 2026 net income $51 million vs. $52 million a year earlier; adjusted EPS $1.77 vs. $1.60
Q2 2026 guidance: revenue $735 million to $750 million; GAAP EPS $1.53 to $1.63; adjusted EPS $1.95 to $2.05, excluding RUCKUS
Broadridge reported fiscal third-quarter 2026 results for the period ended March 31, 2026, with total revenue up 8% to $1,954 million and diluted EPS up 15% to $2.36. The company raised two fiscal 2026 guidance measures but lowered its closed sales outlook, and it completed its acquisition of CQG on April 30, 2026.
Total revenue rose 8% to $1,954 million; diluted EPS rose 15% to $2.36 and Adjusted EPS rose 11% to $2.72.
Operating income rose 4% to $359 million, but operating margin fell to 18.4% from 19.0%.
FY26 guidance: recurring revenue growth at constant currency raised to at or above 7%; Adjusted EPS growth raised to 10-12% from 9-12%.
FY26 closed sales guidance revised down to $240-290 million from $290-330 million.
Organon reported first-quarter 2026 revenue of $1.460 billion, down 4% from $1.513 billion a year earlier and down 9% excluding foreign currency, while GAAP net income rose to $146 million from $87 million. Non-GAAP adjusted diluted EPS fell to $0.71 from $1.02, and the company will not provide financial guidance because of its pending all-cash merger into Sun Pharma, which is expected to close in early 2027.
Revenue was $1.460 billion, down 4% as reported and down 9% excluding foreign currency, from $1.513 billion in Q1 2025.
GAAP diluted EPS was $0.55 versus $0.33; non-GAAP adjusted diluted EPS was $0.71 versus $1.02.
Board declared a quarterly dividend of $0.02 per share, payable June 11, 2026, to holders of record on May 11, 2026.
No financial guidance or earnings call due to the pending Sun Pharma merger, expected to close in early 2027 subject to regulatory and stockholder approval.
APi Group reported first-quarter 2026 net revenues of $1.98 billion, up 15.3% from a year earlier, or 10.4% on an organic basis. Net income rose 62.9% to $57 million, and adjusted diluted EPS rose 28.0% to $0.32. The company raised its full-year 2026 guidance for net revenues and adjusted EBITDA.
Adjusted EBITDA rose 21.8% to $235 million, and adjusted EBITDA margin increased 70 basis points to 11.9%.
Full-year 2026 net revenue guidance was raised to $8.475 billion to $8.675 billion, from $8.400 billion to $8.600 billion.
Full-year 2026 adjusted EBITDA guidance was raised to $1.150 billion to $1.210 billion, from $1.140 billion to $1.200 billion.
Second-quarter 2026 guidance calls for net revenues of $2.175 billion to $2.225 billion and adjusted EBITDA of $300 million to $310 million.
LKQ reported first quarter 2026 revenue up 4.3% to $3,469 million, but diluted EPS fell 50.8% to $0.30, including a $44 million impairment on its Mekonomen equity investment. The company cut its GAAP diluted EPS outlook to $2.16 to $2.46 from $2.35 to $2.65, while keeping its adjusted EPS outlook at $2.90 to $3.20, and said its board is reviewing strategic alternatives.
Q1 2026 revenue was $3,469 million, up 4.3% from $3,327 million; parts and services organic revenue fell 1.6%.
Q1 diluted EPS was $0.30 versus $0.61; adjusted diluted EPS was $0.67 versus $0.74, down 9.5%.
Full-year 2026 GAAP diluted EPS outlook was lowered to $2.16 to $2.46 from $2.35 to $2.65; adjusted diluted EPS outlook of $2.90 to $3.20 was unchanged.
Free cash flow was negative $96 million in Q1; the board declared a $0.30 per share dividend payable June 4, 2026.
ConocoPhillips reported first-quarter 2026 earnings of $2.2 billion, or $1.78 per share, down from $2.8 billion, or $2.23 per share, a year earlier. Adjusted earnings were $2.3 billion, or $1.89 per share, versus $2.7 billion, or $2.09 per share, as lower gas prices in the Permian and lower volumes outweighed lower costs. The company also updated its 2026 production and capital guidance and declared a $0.84 per share second-quarter dividend.
Q1 2026 earnings $2.2 billion ($1.78 per share) vs. $2.8 billion ($2.23 per share) in Q1 2025
Q1 2026 total company production of 2,309 MBOED, down 80 MBOED from a year earlier
Full-year 2026 production guidance of 2.295 to 2.325 MMBOED; 2026 capital spending expected at $12 to $12.5 billion
Second-quarter ordinary dividend of $0.84 per share, payable June 1, 2026, to holders of record on May 11, 2026
Baxter reported first-quarter 2026 sales of $2.7 billion, up 3% on a reported basis but down 1% on an organic basis. The company posted a U.S. GAAP loss from continuing operations of $17 million, or $0.03 per diluted share, compared with income of $64 million a year earlier, and its adjusted diluted EPS fell 35% to $0.36. Shareholders face weaker profit even as the company reiterated its full-year 2026 outlook and declared a $0.01 quarterly dividend.
Sales from continuing operations were $2.7 billion, up 3% reported and down 1% organic; U.S. sales fell 4% to about $1.44 billion.
U.S. GAAP loss from continuing operations was $17 million, or $0.03 per diluted share, versus income of $64 million in the prior-year quarter.
Adjusted diluted EPS from continuing operations was $0.36, down 35% from $0.55, with management citing tariffs, higher manufacturing costs and a prior-year timing benefit.
Full-year 2026 adjusted EPS outlook of $1.85 to $2.05 was reiterated; the Board declared a $0.01 dividend payable July 1, 2026, to holders of record May 29, 2026.
International Paper reported preliminary first-quarter 2026 net sales of $5.97 billion, up from $5.26 billion a year earlier, and earnings from continuing operations of $76 million, compared with a loss of $124 million in the first quarter of 2025. Adjusted EBITDA from continuing operations fell to $677 million from $689 million, and the company updated its full-year 2026 adjusted EBITDA target to $3.20 billion to $3.50 billion, citing a tougher macro environment and a severe winter storm.
Q1 2026 net sales of $5.97 billion vs. $5.26 billion in Q1 2025; diluted EPS from continuing operations of $0.14 vs. a loss of $0.28
Adjusted operating EPS of $0.15 vs. $0.17 in Q1 2025; adjusted EBITDA of $677 million vs. $689 million
Updated 2026 targets: second-quarter adjusted EBITDA of $520 million to $570 million; full-year adjusted EBITDA of $3.20 billion to $3.50 billion
Received $1.1 billion in net proceeds from the sale of the Global Cellulose Fibers business and paid down $660 million of debt; separation of the EMEA packaging business is ongoing
Crocs reported first-quarter 2026 revenue of $921 million, down 1.7% from a year earlier, and diluted earnings per share of $2.71, down from $2.83. The company raised its full-year 2026 adjusted diluted EPS guidance to $13.20 to $13.75 from $12.88 to $13.35, citing the first-quarter results.
Q1 2026 revenue of $921 million, down 1.7%; direct-to-consumer revenue grew 12.1%, wholesale fell 9.9%
GAAP diluted EPS of $2.71 vs. $2.83; adjusted diluted EPS of $2.99 vs. $3.00
Full-year 2026 adjusted diluted EPS guidance raised to $13.20 to $13.75 from $12.88 to $13.35
Q2 2026 adjusted diluted EPS guidance of $4.15 to $4.35; repurchased $73.6 million of shares from March 31 through April 23, 2026
CNX reported first-quarter 2026 net income of $348.1 million, or $2.18 per diluted share, compared with a net loss of $197.7 million in the first quarter of 2025. The company also lowered its 2026 guidance for Adjusted EBITDAX and free cash flow, citing a lower NYMEX natural gas price assumption, which matters to shareholders because it reduces the cash the company expects to generate this year.
Q1 2026 net income was $348.1 million, or $2.18 per diluted share, versus a net loss of $197.7 million, or $1.34 per share, in Q1 2025.
Total revenue and other operating income was $786.7 million, up from $610.5 million in Q4 2025.
2026 Adjusted EBITDAX guidance was lowered to $1,265 million to $1,315 million from $1,310 million to $1,360 million; free cash flow guidance was lowered to about $525 million from about $550 million.
Q1 2026 included a realized commodity derivative loss of $222 million, and the 2026 NYMEX natural gas price assumption was lowered to $3.64 per MMBtu from $4.07.
Eli Lilly reported first-quarter 2026 revenue of $19.8 billion, up 56% from a year earlier, and reported EPS of $8.26 versus $3.06. The company raised its full-year 2026 revenue guidance to $82.0 billion to $85.0 billion and its non-GAAP EPS guidance to $35.50 to $37.00, which matters to shareholders because it raises the company's own outlook for the year.
Q1 2026 revenue was $19.8 billion, up 56% from $12.7 billion, driven by a 65% increase in volume, partly offset by a 13% decrease from lower realized prices.
Reported EPS was $8.26 versus $3.06; non-GAAP EPS was $8.55 versus $3.34.
Full-year 2026 revenue guidance rose to $82.0 billion to $85.0 billion from $80 billion to $83 billion; non-GAAP EPS guidance rose to $35.50 to $37.00 from $33.50 to $35.00.
Reported gross margin was 81.9% of revenue, down 0.6 percentage points, primarily due to lower realized prices.
Martin Marietta reported first-quarter 2026 revenues of $1.362 billion, up 17%, but net earnings from continuing operations fell 24% to $79 million, with diluted EPS of $1.31 versus $1.70. The company reaffirmed full-year 2026 guidance and agreed on April 19, 2026 to acquire New Frontier Materials, while reported net earnings of $1.513 billion included a $1.4 billion after-tax gain on the QUIKRETE asset exchange.
Revenues rose 17% to $1.362 billion; adjusted EBITDA from continuing operations rose 14% to $364 million.
Adjusted earnings per diluted share from continuing operations were $1.93, up 14%, excluding charges totaling $0.62 per share.
Full-year 2026 adjusted EBITDA guidance of $2.43 billion at the midpoint was reaffirmed.
The New Frontier Materials acquisition is expected to close in the second half of 2026, subject to regulatory approvals.
Option Care Health reported first quarter 2026 net revenue of $1,350.7 million, up 1.3%, while adjusted EBITDA fell 6.3% to $104.8 million and adjusted diluted EPS was flat at $0.40. The company adjusted its full-year 2026 net revenue guidance to $5.675 billion to $5.775 billion and its cash flow target to at least $320 million, while keeping adjusted EBITDA and adjusted EPS guidance in place, which matters to shareholders because the revenue outlook has changed while profit measures are unchanged.
Q1 2026 net revenue of $1,350.7 million, up 1.3%; GAAP net income of $45.3 million, down 3.0%
Adjusted EBITDA of $104.8 million, down 6.3%; adjusted diluted EPS of $0.40, flat year over year
Full-year 2026 guidance: net revenue $5.675 billion to $5.775 billion; adjusted diluted EPS $1.82 to $1.92; adjusted EBITDA $480 million to $505 million
Cash used in operating activities was $12.1 million in Q1; Company repurchased $17.5 million of stock and expanded its revolving credit facility from $400 million to $850 million
Quanta Services reported first-quarter 2026 revenue of $7.87 billion, up from $6.23 billion a year earlier, and net income attributable to common stock of $220.6 million, or $1.45 per diluted share, versus $0.96 in the first quarter of 2025. The company said it is increasing its full-year 2026 financial expectations, which now include revenue of $34.7 billion to $35.2 billion and diluted EPS of $9.17 to $9.87.
Q1 2026 revenue was $7.87 billion, compared with $6.23 billion in Q1 2025.
Q1 diluted EPS was $1.45 versus $0.96; adjusted diluted EPS was $2.68 versus $1.78.
Full-year 2026 revenue is now expected at $34.7 billion to $35.2 billion, and diluted EPS at $9.17 to $9.87.
Backlog reached a record $48.5 billion at March 31, 2026; Q1 cash flow from operations was $391.7 million.
Labcorp reported first-quarter 2026 revenue of $3.54 billion, up 5.8% from $3.35 billion a year earlier, and diluted EPS of $3.35 versus $2.52. The company raised its full-year 2026 revenue and adjusted EPS guidance, with the adjusted EPS range now $17.70 to $18.35 from $17.55 to $18.25. Headline profit and revenue measures improved, while total debt rose to $6.33 billion at quarter end due to pre-funding of maturing debt.
Q1 2026 revenue $3.54 billion vs. $3.35 billion, up 5.8%; diluted EPS $3.35 vs. $2.52
Q1 2026 adjusted EPS $4.25 vs. $3.84, up 10.6%
Full-year 2026 adjusted EPS guidance raised to $17.70–$18.35 from $17.55–$18.25; revenue guidance raised to 5.0%–6.1% growth
Quarterly dividend of $0.72 per share declared April 9, 2026, payable June 11, 2026 to holders of record May 29, 2026
L3Harris reported first quarter 2026 revenue of $5.7 billion, up 12% from a year earlier, and GAAP diluted EPS of $2.72, up 33%. The company raised its 2026 EPS guidance to $11.40-$11.60 from $11.30-$11.50, but free cash flow was negative $187 million in the quarter.
Revenue of $5,744 million, up from $5,132 million in the first quarter of 2025; organic growth of 15%
GAAP diluted EPS of $2.72 versus $2.04 a year earlier; operating margin 11.4%, up 120 bps
2026 EPS guidance raised to $11.40-$11.60 from $11.30-$11.50; free cash flow guidance of $3.0 billion unchanged
Cash used in operations was $95 million; free cash flow was negative $187 million versus negative $101 million a year earlier
Hyatt reported first quarter 2026 net income attributable to the company of $38 million, or $0.40 diluted EPS, compared with $20 million, or $0.19, a year earlier, and raised parts of its full-year 2026 outlook, including RevPAR and gross fees. Adjusted EBITDA guidance of $1,155 million to $1,205 million was also issued, though the company expects Distribution segment Adjusted EBITDA to decline by about $25 million in 2026.
Q1 2026 gross fees were $333 million, up 8.6% from the first quarter of 2025, and total revenues were $1,748 million versus $1,718 million.
Full-year 2026 outlook: comparable system-wide hotels RevPAR growth of 2.0% to 4.0%, gross fees of $1,305 million to $1,335 million, and net income of $255 million to $350 million.
The company repurchased $135 million of Class A common stock in the quarter and declared a $0.15 per share dividend payable June 11, 2026.
Hyatt revised its Adjusted EBITDA definition, and prior-period results were recast for comparability.
Merck reported first-quarter 2026 sales of $16.3 billion, up 5%, but posted a GAAP loss of $1.72 per share versus earnings of $2.01 a year earlier, driven by a $3.62 per share charge for the acquisition of Cidara Therapeutics. The company raised the midpoint of its full-year 2026 sales range and raised its non-GAAP EPS range to $5.04 to $5.16, but the outlook excludes the expected one-time charge of about $5.8 billion, or about $2.35 per share, tied to the planned Terns Pharmaceuticals acquisition, which is expected to close in May.
Q1 2026 sales were $16.3 billion, up 5% (3% excluding foreign exchange); KEYTRUDA/KEYTRUDA QLEX sales rose 12% to $8.0 billion.
GAAP loss per share was $1.72 and non-GAAP loss per share was $1.28, both including the $3.62 per share Cidara charge; Q1 2025 GAAP EPS was $2.01.
Full-year 2026 sales outlook narrowed to $65.8 billion to $67.0 billion from $65.5 billion to $67.0 billion; non-GAAP EPS outlook raised to $5.04 to $5.16 from $5.00 to $5.15.
Outlook excludes the Terns acquisition, expected to close in May with a one-time charge of about $5.8 billion, or about $2.35 per share.
Air Products reported fiscal second-quarter 2026 results on April 30, 2026, with adjusted EPS of $3.20, up 19% from a year earlier, and sales of $3.2 billion, up 9%. The company raised its full-year fiscal 2026 adjusted EPS guidance to $13.00 to $13.25, which suggests higher expected profit for shareholders, though the company said it remains cautious about the macroeconomic environment.
Q2 fiscal 2026 GAAP EPS was $3.19, compared with a loss of $7.77 a year earlier, which included about $2.9 billion in business and asset action charges.
Adjusted operating income was $753 million, up 19%, and adjusted operating margin was 23.7%, up from 21.6%.
Q3 fiscal 2026 adjusted EPS guidance is $3.25 to $3.35; full-year capital expenditure expectation of about $4.0 billion is unchanged.
Samsung selected Air Products to build, own and operate production facilities and a bulk specialty gas supply system for a new semiconductor fab in South Korea.
Iron Mountain reported first-quarter 2026 total revenue of $1.9 billion, up 21.6% from a year earlier, and net income of $149 million, compared with $16 million in the first quarter of 2025. The company raised its full-year 2026 guidance for total revenue, adjusted EBITDA and AFFO per share, and its board declared a quarterly dividend of $0.864 per share payable July 3, 2026.
Total revenue was $1,936 million, up 21.6% as reported and 18.6% excluding foreign exchange.
Net income was $149 million, or $0.48 per diluted share, versus $16 million, or $0.05, a year earlier.
Adjusted EBITDA was $708 million, up 22.1%, and AFFO was $426 million, or $1.43 per share.
Full-year 2026 total revenue guidance is $7,825 million to $7,925 million, up from $7,625 million to $7,775 million; AFFO per share guidance is $5.79 to $5.86, up from $5.69 to $5.79.
Cardinal Health reported third-quarter fiscal 2026 revenue of $60.9 billion, up 11%, and non-GAAP diluted EPS of $3.17, up 35%. GAAP diluted EPS fell 20% to $1.69, reflecting a $184 million pre-tax goodwill impairment at its Navista & ION unit, and the company raised and narrowed its fiscal 2026 non-GAAP EPS guidance to $10.70 to $10.80.
Revenue rose 11% to $60.9 billion; GAAP operating earnings fell 30% to $509 million
Non-GAAP diluted EPS rose 35% to $3.17; GAAP diluted EPS fell 20% to $1.69
$184 million pre-tax goodwill impairment in the Navista & ION reporting unit drove the GAAP decline
Fiscal 2026 non-GAAP EPS guidance raised and narrowed to $10.70 to $10.80; the company also completed an additional $250 million share repurchase, bringing its fiscal 2026 total to $1.0 billion
Granite reported first-quarter 2026 revenue of $912 million, up 30% from a year earlier, and raised its 2026 revenue guidance to $5.2 billion to $5.4 billion. The GAAP net loss widened to $42 million, but adjusted diluted EPS rose to $0.26 from $0.01, and the company said it completed the Kenny Seng Construction acquisition on April 23, 2026.
Q1 revenue was $912 million, up from $700 million; net loss attributable to Granite was $42 million, or $(0.96) per diluted share, versus $34 million, or $(0.77), a year earlier
Adjusted diluted EPS was $0.26 versus $0.01; adjusted EBITDA rose 106% to $58 million
2026 revenue guidance raised to $5.2 billion to $5.4 billion from $4.9 billion to $5.1 billion; adjusted EBITDA margin guidance raised to 12.25% to 13.25%
Contracted backlog (CAP) reached a record $7.2 billion, including $640 million of U.S. Customs and Border Protection tactical infrastructure projects
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.